Fig. 4From: MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancerCurrent treatment options for EGFR-mutant NSCLCs and potential strategies for overcoming acquired resistance to osimertinib. The strategies as indicated with dashed lines need clinical validation. METi, MET inhibitor; MEKi, MEK inhibitorBack to article page